Case Number:

IPR2022-00796

Case Type:

IPR

Status:

Final Written Decision

Petitioner:

Eli Lilly and Company

1. Filed: April 11, 2022 00:00

   Coverage

   1. October 12, 2023

      Eli Lilly Continues Migraine IP Wins Over Teva With PTAB Ax

      Eli Lilly has persuaded the Patent Trial and Appeal Board to invalidate a Teva Pharmaceuticals patent for the migraine drug Ajovy, shortly after a Massachusetts federal judge overturned a related $176.5 million verdict against Eli Lilly.

   1 other articles on this case. View all »

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login